PTC Therapeutics (FRA:BH3) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BH3 PTC Therapeutics Inc FRA:BH3
57 GF Score
Price €56.60
GF Value €33.48
! 7 Warning Signs
View Full Analysis

What is PTC Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


PTC Therapeutics  (FRA:BH3) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


PTC Therapeutics Cyclically Adjusted PB Ratio Related Terms


PTC Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for PTC Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics Cyclically Adjusted PB Ratio Chart

PTC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.48 6.97 7.10 32.77 225.52

PTC Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.66 35.44 55.03 58.19 90.11

FRA:BH3 vs XENE, DNTH, MIRM: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, PTC Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:BH3
57GF Score
PTC Therapeutics Inc FRA:BH3
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTC Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

PTC Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, PTC Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.736/333.9520*333.9520
=-1.736

Current CPI (Jun. 2026) = 333.9520.

PTC Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.651 241.428 5.050
201612 3.318 241.432 4.590
201703 2.747 243.801 3.763
201706 3.603 244.955 4.912
201709 2.976 246.819 4.027
201712 3.131 246.524 4.241
201803 2.923 249.554 3.912
201806 4.906 251.989 6.502
201809 6.591 252.439 8.719
201812 6.063 251.233 8.059
201903 7.820 254.202 10.273
201906 7.310 256.143 9.531
201909 9.886 256.759 12.858
201912 8.549 256.974 11.110
202003 7.678 258.115 9.934
202006 7.581 257.797 9.820
202009 6.426 260.280 8.245
202012 5.650 260.474 7.244
202103 3.536 264.877 4.458
202106 2.349 271.696 2.887
202109 1.281 274.310 1.560
202112 0.018 278.802 0.022
202203 -1.141 287.504 -1.325
202206 -2.438 296.311 -2.748
202209 -3.223 296.808 -3.626
202212 -4.449 296.797 -5.006
202303 -5.690 301.836 -6.295
202306 -7.049 305.109 -7.715
202309 -8.396 307.789 -9.110
202312 -9.788 306.746 -10.656
202403 -10.798 312.332 -11.545
202406 -11.893 314.175 -12.642
202409 -12.277 315.301 -13.003
202412 -13.647 315.605 -14.440
202503 -2.171 319.799 -2.267
202506 -2.217 322.561 -2.295
202509 -1.658 324.800 -1.705
202512 -2.146 324.054 -2.212
202603 -1.890 330.213 -1.911
202606 -1.736 333.952 -1.736

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €56.60 is trading 69.1% above its estimated GF Value™ of €33.48.

Key valuation signals for FRA:BH3:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €33.48 vs. price of €56.60 (69.1% above fair value)
  • GF Score™: 57/100 with 7 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
57GF Score

Get the complete analysis for FRA:BH3

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.60
Price
€33.48
GF Value